Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Wu

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Journal of Adolescent and Young Adult Oncology|March 17, 2016
A Study Protocol for the Australasian Oncofertility Registry: Monitoring Referral Patterns and the Uptake, Quality, and Complications of Fertility Preservation Strategies in Australia and New ZealandAntoinette C Anazodo, Catharyn J Stern, Robert I McLachlan, et al.
Haematologica|February 16, 2015
The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromesMichaela Cada, Catherin I Segbefia, Robert Klaassen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal for Immunotherapy of Cancer|June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumorsJayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
Clinical Immunology (Orlando, Fla.)|January 4, 2017
The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosusRobert J Ragotte, Anita Dhanrajani, Julian Pleydell-Pearce, et al.
Journal of Medical Genetics|July 3, 2015
Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromesIbrahim Ghemlas, Hongbing Li, Bozana Zlateska, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
F1000Research|June 25, 2016
Enhancement of COPD biological networks using a web-based collaboration interface, Stephanie Boue, Brett Fields, et al.
Nature|November 15, 2013
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptorsDavid J Lloyd, David J St Jean, Robert J M Kurzeja, et al.
The Lancet. HIV|August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialPatrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Journal of Adolescent and Young Adult Oncology|March 17, 2016
A Study Protocol for the Australasian Oncofertility Registry: Monitoring Referral Patterns and the Uptake, Quality, and Complications of Fertility Preservation Strategies in Australia and New ZealandAntoinette C Anazodo, Catharyn J Stern, Robert I McLachlan, et al.
Haematologica|February 16, 2015
The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromesMichaela Cada, Catherin I Segbefia, Robert Klaassen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal for Immunotherapy of Cancer|June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumorsJayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
Clinical Immunology (Orlando, Fla.)|January 4, 2017
The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosusRobert J Ragotte, Anita Dhanrajani, Julian Pleydell-Pearce, et al.
Journal of Medical Genetics|July 3, 2015
Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromesIbrahim Ghemlas, Hongbing Li, Bozana Zlateska, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
F1000Research|June 25, 2016
Enhancement of COPD biological networks using a web-based collaboration interface, Stephanie Boue, Brett Fields, et al.
Nature|November 15, 2013
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptorsDavid J Lloyd, David J St Jean, Robert J M Kurzeja, et al.
The Lancet. HIV|August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialPatrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Pageof 15